Expression of RACK1 and EGP40 in oral squamous cell carcinoma and its correlation with clinicopathological features and prognosis

doi:10.19439/j.sjos.2023.04.009

Abstract

Abstract: PURPOSE: To investigate the expression of tissue-active protein kinase C receptor 1 (RACK1) and epithelin glycoprotein 40 (EGP40) in oral squamous cell carcinoma (OSCC) and their relationship with clinicopathological features and prognosis. METHODS: A total of 103 patients with OSCC who were admitted to Shangrao People's Hospital from January 2016 to February 2019 were prospectively selected as the research subjects. All patients underwent radical resection of OSCC and were followed up for 3 years. Immunohistochemistry was used to detect the positive expression levels of RACK1 and EGP40 in cancer tissues and adjacent tissues. The positive expression of RACK1 and EGP40 in cancer tissues and adjacent tissues were compared. The relationship between the positive expression level of RACK1 and EGP40 in cancer tissues of OSCC patients and clinicopathological parameters was analyzed. Factors affecting postoperative recurrence and metastasis in OSCC patients were analyzed. The relationship between the expression of RACK1 and EGP40 in cancer tissues and postoperative disease-free survival of OSCC patients was analyzed. SPSS 18.0 software package was used for statistical analysis of the data. RESULTS: The positive expression rate of RACK1 and EGP40 in cancer tissues was significantly higher than those in adjacent tissues (P<0.05). The positive expression rate of RACK1 and EGP40 in cancer tissues of OSCC patients with poorly differentiated, stage III, cervical lymph node metastasis, and infiltrating vessels was significantly higher than that in patients with moderate and high differentiation, stage II, no cervical lymph node metastasis, and no infiltrating vessels(P<0.05). The positive expression rate of RACK1 in cancer tissue of OSCC patients in T3 stage was significantly higher than that in T2 stage(P<0.05). Cox multivariate regression analysis showed pathological grade (RR=6.290, 95%CI: 2.588-15.287), cervical lymph node metastasis(RR=5.995, 95%CI: 2.467-14.571), RACK1 positive rate (RR=4.495, 95%CI: 1.850-10.925) and EGP40 positive rate (RR=4.559, 95%CI: 1.876-11.079) were factors affecting the recurrence and metastasis of OSCC patients after surgery(P<0.05). The disease-free survival curve of patients with negative expression of RACK1 was significantly better than that of patients with positive expression (P<0.05). The disease-free survival curve of patients with negative expression of EGP40 was significantly better than that of patients with positive expression (P<0.05). CONCLUSIONS: The expression of RACK1 and EGP40 in cancer tissues of OSCC patients is related to clinicopathological parameters and prognosis. Patients with positive expression of RACK1 and EGP40 have a high risk of recurrence and metastasis after surgery.

Key words: Oral squamous cell carcinoma, RACK1, EGP40, Pathological features, Prognosis

CLC Number:

R739.8

DUAN Yong-hua, WU Kai-liu, MEI Jian, ZHOU Yi-yuan, LIU Meng-shi. Expression of RACK1 and EGP40 in oral squamous cell carcinoma and its correlation with clinicopathological features and prognosis[J]. Shanghai Journal of Stomatology, 2023, 32(4): 385-390.

References

[1] Hasegawa K, Fujii S, Matsumoto S, et al.YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation[J]. J Pathol, 2021, 253(1): 80-93.
[2] Melo BAC, Vilar LG, Oliveira NR, et al.Human papillomavirus infection and oral squamous cell carcinoma-a systematic review[J]. Braz J Otorhinolaryngol, 2021, 87(3): 346-352.
[3] Yoshimoto S, Morita H, Matsuda M, et al.NFAT5 promotes oral squamous cell carcinoma progression in a hyperosmotic environment[J]. Lab Invest, 2021, 101(1): 38-50.
[4] DeLucia DC, Cardillo TM, Ang L, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer[J]. Clin Cancer Res, 2021, 27(3): 759-774.
[5] 陈立智, 胡军, 傅厚丰, 等. L1细胞黏附分子在结肠癌中表达的临床意义和生物学作用[J]. 实用医学杂志, 2020, 36(19): 2690-2695.
[6] Srichinthu KK, Kumar GS, Prasad H, et al.Expression of epithelial glycoprotein (EGP40) in oral epithelial dysplasia and oral squamous cell carcinoma (OSCC)[J]. Indian J Dent Res, 2020, 31(5): 738-742.
[7] Yu Z, Jiang X, Qin L, et al.A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination[J]. Oncogene, 2021, 40(5): 1027-1042.
[8] Wu B, Chang N, Xi H, et al.PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer[J]. Theranostics, 2021, 11(7): 3150-3166.
[9] 许立霞, 付强, 胡明星, 等. 活化激酶C受体1对胆管癌细胞迁移和侵袭能力的影响[J]. 中华实验外科杂志, 2021, 38(6): 1079-1081.
[10] 中华口腔医学会口腔颌面外科专业委员会肿瘤学组. 口腔颌面部恶性肿瘤治疗指南[J]. 中国口腔颌面外科杂志, 2010, 3(7): 395-403.
[11] Shojaeian S, Moazeni-Roodi A, Allameh A, et al.Methylation of TGM-3 promoter and its association with oral squamous cell carcinoma (OSCC)[J]. Avicenna J Med Biotechnol, 2021, 13(2): 65-73.
[12] Yang J, Isaji T, Zhang G, et al.EpCAM associates with integrin and regulates cell adhesion in cancer cells[J]. Biochem Biophys Res Commun, 2020, 522(4): 903-909.
[13] Gong X, Tang H, Yang K.PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex[J]. Cell Death Dis, 2021, 12(3): 276-291.
[14] Buoso E, Masi M, Racchi M, et al.Endocrine-disrupting chemicals' (EDCs) effects on tumour microenvironment and cancer progression: emerging contribution of RACK1[J]. Int J Mol Sci, 2020, 21(23): 9229-9232.
[15] Lopez-Nunez O, Ranganathan S.Immunohistochemical expression analysis of EpCAM in hepatoblastomas[J]. Appl Immunohistochem Mol Morphol, 2020, 28(9): 711-718.
[16] Dan H, Liu S, Liu J, et al.RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-κB pathway in oral squamous cell carcinoma[J]. Mol Oncol, 2020, 14(4): 795-807.